June 2022

Multiple Options Mean More Time for Patients With Indolent Lymphoma

June 21, 2022

The treatment landscape for relapsed/refractory MZL and follicular lymphoma (FL) is shifting from intravenous chemotherapy and monoclonal antibodies to oral oncolytic therapy or CD19-directed chimeric antigen receptor (CAR) T-cell therapy.